- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 0.0 | -100.0 | 0.0 | 0.02 | 0.0 | 0.02 | N/A | 本年累計營收成長,主係本年度新增研發用藥收入,致使累計營收較去年同期增加。 | ||
| 2026/3 | 0.02 | 0.0 | 0.0 | 0.02 | 0.0 | 0.02 | 13.39 | 本月營收較去年同期增加,係因本月認列臨床藥物收入所致。 | ||
| 2026/2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.02 | 11.93 | 本公司屬新藥研發公司,本月無營收。 | ||
| 2026/1 | 0.0 | -100.0 | 0.0 | 0.0 | 0.0 | 0.48 | 0.5 | 本公司屬新藥研發公司,本月無營收。 | ||
| 2025/12 | 0.02 | -95.58 | -54.44 | 0.67 | -59.85 | 0.48 | 0.42 | 本月營收較去年同期減少,主係去年同期認列較高銷貨收入;本年累計營收較去年減少,主係去年認列歐洲等區域授權簽約金所致。 | ||
| 2025/11 | 0.46 | 0.0 | 0.0 | 0.65 | -60.0 | 0.46 | 0.44 | 本月營收較去年同期增加,係因本月認列臨床藥物收入;本年累計營收較去年減少,係因去年認列歐洲等區域授權簽約金所致。 | ||
| 2025/10 | 0.0 | 0.0 | -100.0 | 0.2 | -87.94 | 0.0 | 0 | 本月營收較去年同期減少,係因去年同期認列歐洲等區域授權簽約金,致本月營收及累計營收較去年同期減少。 | ||
| 2025/9 | 0.0 | 0.0 | -100.0 | 0.2 | -61.05 | 0.04 | 9.26 | 本月營收較去年同期減少,係因去年同期認列銷貨收入;本年累計營收較去年減少,係因去年累計認列銷貨收入較高所致。。 | ||
| 2025/8 | 0.0 | -100.0 | 0.0 | 0.2 | 104.56 | 0.04 | 9.26 | 累計營收較去年同期增加,係因認列銷貨收入較高所致。 | ||
| 2025/7 | 0.04 | 0.0 | 0.0 | 0.2 | 104.56 | 0.2 | 1.88 | 本月及累計營收較去年同期增加,係因認列銷貨收入較高所致。 | ||
| 2025/6 | 0.0 | -100.0 | 0.0 | 0.16 | 63.02 | 0.16 | 2.1 | 累計營收較去年同期增加,係因認列銷貨收入較高所致。 | ||
| 2025/5 | 0.16 | 0.0 | 64.3 | 0.16 | 63.02 | 0.16 | 2.1 | 本月及累計營收較去年同期增加,係因本月認列銷貨收入較高所致。 | ||
| 2025/4 | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.0 | 0 | 本年累計營收較去年減少,係因去年認列銷貨收入。 | ||
| 2025/3 | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.0 | 0 | 本年累計營收較去年減少,係因去年認列銷貨收入。 | ||
| 2025/2 | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.04 | 7.92 | 本年累計營收較去年減少,係因去年認列銷貨收入。 | ||
| 2025/1 | 0.0 | -100.0 | -100.0 | 0.0 | -100.0 | 0.04 | 7.92 | 本月營收較去年同期減少,係因去年本月認列銷貨收入。 | ||
| 2024/12 | 0.04 | 0.0 | 0.0 | 1.68 | -46.71 | 1.17 | 0.21 | 本月營收較去年同期增加,係因本月認列銷貨收入;本年累計較去年同期減少,係因前期認列授權簽約金收入。 | ||
| 2024/11 | 0.0 | -100.0 | 0.0 | 1.63 | -48.12 | 1.54 | 0.16 | 本年累計較去年同期減少,係因前期認列授權簽約金收入較高所致。 | ||
| 2024/10 | 1.13 | 175.35 | 0.0 | 1.63 | -48.12 | 1.54 | 0.16 | 本月營收較去年同期增加,係因本月認列授權簽約金收入;本年累計較去年同期減少,係因前期認列授權簽約金收入較高所致。 | ||
| 2024/9 | 0.41 | 0.0 | 0.0 | 0.51 | -83.93 | 0.41 | 0.46 | 本月營收較去年同期增加,係因本月認列銷貨收入;本年累計較去年同期減少,係因前期認列授權簽約金收入。 | ||
| 2024/8 | 0.0 | 0.0 | 0.0 | 0.1 | -96.94 | 0.0 | 0 | 去年係因認列授權簽約金收入。 | ||
| 2024/7 | 0.0 | 0.0 | -100.0 | 0.1 | -96.94 | 0.1 | 1.99 | 去年同期係因認列授權簽約金收入。 | ||
| 2024/6 | 0.0 | -100.0 | 0.0 | 0.1 | 0.0 | 0.1 | 3.77 | 銷售L606研發用藥及保健食品 | ||
| 2024/5 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 3.77 | 銷售L606研發用藥 | ||
| 2024/4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 銷售保健食品之營收 | ||
| 2024/3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 銷售保健食品之營收 | ||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A |
- 每季的合約負債通常會反應在未來半年到一年後的營收
| 合約負債 QoQ YoY | |||
|---|---|---|---|
免責聲明
本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。